Literature DB >> 16094256

Fine mapping of the 5p13 locus linked to schizophrenia and schizotypal personality disorder in a Puerto Rican family.

Irina N Bespalova1, Gary W Angelo, Martina Durner, Christopher J Smith, Larry J Siever, Joseph D Buxbaum, Jeremy M Silverman.   

Abstract

A locus involved in schizophrenia and related disorders in a Puerto Rican family has previously been mapped to chromosome 5p. The maximum two-point log of the odds (LOD) score of 3.72 was obtained for marker D5S111, and increased to 4.37 by multipoint analysis, assuming autosomal dominant inheritance with 90% penetrance. Additional genotyping and haplotype analysis placed the novel locus on 5p13.2-p13.3 within the interval between markers D5S1993 and D5S631. In the current study, we saturated the interval between markers D5S1993 and D5S631 with densely spaced polymorphic markers, genotyped these markers in the most informative branch of the family, and narrowed the critical region to 2.8 Mb. G-protein-coupled receptor gene [somatostatin and angiotensin-like peptide receptor (SALPR)] is one of the candidate genes within the critical interval. Sequence analysis of the coding region and the putative promoter of somatostatin and angiotensin-like peptide receptor did not reveal functionally significant variants in affected family members, although several polymorphisms were detected.

Entities:  

Mesh:

Year:  2005        PMID: 16094256     DOI: 10.1097/00041444-200509000-00012

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  11 in total

1.  Genetic variations in the ADAMTS12 gene are associated with schizophrenia in Puerto Rican patients of Spanish descent.

Authors:  Irina N Bespalova; Gary W Angelo; Ben P Ritter; Jason Hunter; Maria L Reyes-Rabanillo; Larry J Siever; Jeremy M Silverman
Journal:  Neuromolecular Med       Date:  2012-02-10       Impact factor: 3.843

Review 2.  Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways.

Authors:  M L Halls; E T van der Westhuizen; R A D Bathgate; R J Summers
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

3.  Non-synonymous variants in the AMACR gene are associated with schizophrenia.

Authors:  Irina N Bespalova; Martina Durner; Benjamin P Ritter; Gary W Angelo; Enrique Rossy-Fullana; Jose Carrion-Baralt; James Schmeidler; Jeremy M Silverman
Journal:  Schizophr Res       Date:  2010-09-26       Impact factor: 4.939

Review 4.  Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.

Authors:  Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-06       Impact factor: 3.568

5.  Mutation analysis of the C1QTNF3 gene in patients with schizophrenia.

Authors:  Irina Bespalova; Gary Angelo; Benjamin Ritter; Enrique Rossy-Fullana; Jose Carrion-Baralt; Martina Durner; Jeremy Silverman
Journal:  Psychiatry Res       Date:  2010-05-18       Impact factor: 3.222

6.  Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample.

Authors:  Brian K Suarez; Jubao Duan; Alan R Sanders; Anthony L Hinrichs; Carol H Jin; Cuiping Hou; Nancy G Buccola; Nancy Hale; Ann N Weilbaecher; Deborah A Nertney; Ann Olincy; Susan Green; Arthur W Schaffer; Christopher J Smith; Dominique E Hannah; John P Rice; Nancy J Cox; Maria Martinez; Bryan J Mowry; Farooq Amin; Jeremy M Silverman; Donald W Black; William F Byerley; Raymond R Crowe; Robert Freedman; C Robert Cloninger; Douglas F Levinson; Pablo V Gejman
Journal:  Am J Hum Genet       Date:  2006-01-03       Impact factor: 11.025

7.  Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia.

Authors:  Daniel R Garton; Ana R Montaño-Rodríguez; Soophie Olfat; Kärt Mätlik; Feride Eren; Laoise Casserly; Anastasios Damdimopoulos; Anne Panhelainen; L Lauriina Porokuokka; Jaakko J Kopra; Giorgio Turconi; Nadine Schweizer; Erika Bereczki; Fredrik Piehl; Göran Engberg; Simon Cervenka; T Petteri Piepponen; Fu-Ping Zhang; Petra Sipilä; Johan Jakobsson; Carl M Sellgren; Sophie Erhardt; Jaan-Olle Andressoo
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 15.992

8.  Exome sequences of multiplex, multigenerational families reveal schizophrenia risk loci with potential implications for neurocognitive performance.

Authors:  Mark Z Kos; Melanie A Carless; Juan Peralta; Joanne E Curran; Ellen E Quillen; Marcio Almeida; August Blackburn; Lucy Blondell; David R Roalf; Michael F Pogue-Geile; Ruben C Gur; Harald H H Göring; Vishwajit L Nimgaonkar; Raquel E Gur; Laura Almasy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-09-13       Impact factor: 3.568

Review 9.  Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?

Authors:  Craig M Smith; Andrew W Walker; Ihaia T Hosken; Berenice E Chua; Cary Zhang; Mouna Haidar; Andrew L Gundlach
Journal:  Front Pharmacol       Date:  2014-03-21       Impact factor: 5.810

Review 10.  Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity.

Authors:  C Gragnoli; G M Reeves; J Reazer; T T Postolache
Journal:  Transl Psychiatry       Date:  2016-04-19       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.